Two Sigma Securities LLC Buys New Shares in Illumina, Inc. (NASDAQ:ILMN)

Two Sigma Securities LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,717 shares of the life sciences company's stock, valued at approximately $630,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ILMN. Capital World Investors increased its stake in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares during the period. WCM Investment Management LLC grew its holdings in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the period. Norges Bank acquired a new position in Illumina in the fourth quarter valued at about $228,714,000. Finally, Bessemer Group Inc. lifted its position in Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock worth $180,152,000 after purchasing an additional 1,344,038 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ILMN. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Robert W. Baird decreased their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Finally, Barclays lowered their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.55.

Illumina Trading Down 0.9 %

Shares of Illumina stock traded down $0.71 during trading on Thursday, hitting $76.89. The company's stock had a trading volume of 460,740 shares, compared to its average volume of 2,278,492. The stock has a market cap of $12.17 billion, a price-to-earnings ratio of -10.01, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The stock has a 50-day moving average price of $80.77 and a two-hundred day moving average price of $116.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.